Evaluation of the BioFire FilmArray® GastrointestinalPanel in a Midwestern Academic Hospital

C. N. Murphy, R. C. Fowler, Peter Charles Iwen, Paul D Fey

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The BioFire FilmArray® Gastrointestinal Panel (GIP) was implemented to replace traditional stool culture and enzyme immunoassay (EIA) testing for stool pathogens. The purpose of this study was to evaluate the detection rate, incidence of coinfection, and culture recovery rate of gastrointestinal (GI) pathogens detected by the GIP over a 1-year period. A total of 2257 stools collected from January to December 2015 were tested using the GIP. Clostridium difficile colonization was also evaluated by an antigen/toxin EIA and confirmatory polymerase chain reaction (PCR). The GIP detected one pathogen in 911 (40.4%) specimens. Coinfections were detected in 176 (7.8%) of these specimens. The most frequently detected pathogens were C. difficile (15.2%), norovirus (8.9%), enteropathogenic Escherichia coli (7.1%), enteroaggregative E. coli (3.4%), Campylobacter spp. (2.3%), and sapovirus (2.0%). Each of the remaining GIP targets had a detection rate of ≤1.6%. The recovery of bacteria for public health investigations varied, with rates as high as 77% for Salmonella to as low as 30% for Yersinia enterocolitica. Of stools positive for C. difficile on the GIP that were tested by EIA, only 42.7% (88/206) were found to be producing detectable toxin. Overall, the implementation of the GIP resulted in high detection rates of GI pathogens, including the frequent detection of coinfections. This is a promising test to streamline the testing of agents causing infectious gastroenteritis from multiple tests down to a single order with limited hands-on time. Ongoing studies will need to assess the impact that the GIP has on downstream patient care and public health practices.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
DOIs
StateAccepted/In press - Dec 12 2016

Fingerprint

Clostridium difficile
Coinfection
Immunoenzyme Techniques
Sapovirus
Public Health Practice
Norovirus
Enteropathogenic Escherichia coli
Yersinia enterocolitica
Campylobacter
Gastroenteritis
Salmonella
Patient Care
Public Health
Escherichia coli
Bacteria
Antigens
Polymerase Chain Reaction
Incidence

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{462eca241e944f16b3a7301b5fadcb01,
title = "Evaluation of the BioFire FilmArray{\circledR} GastrointestinalPanel in a Midwestern Academic Hospital",
abstract = "The BioFire FilmArray{\circledR} Gastrointestinal Panel (GIP) was implemented to replace traditional stool culture and enzyme immunoassay (EIA) testing for stool pathogens. The purpose of this study was to evaluate the detection rate, incidence of coinfection, and culture recovery rate of gastrointestinal (GI) pathogens detected by the GIP over a 1-year period. A total of 2257 stools collected from January to December 2015 were tested using the GIP. Clostridium difficile colonization was also evaluated by an antigen/toxin EIA and confirmatory polymerase chain reaction (PCR). The GIP detected one pathogen in 911 (40.4{\%}) specimens. Coinfections were detected in 176 (7.8{\%}) of these specimens. The most frequently detected pathogens were C. difficile (15.2{\%}), norovirus (8.9{\%}), enteropathogenic Escherichia coli (7.1{\%}), enteroaggregative E. coli (3.4{\%}), Campylobacter spp. (2.3{\%}), and sapovirus (2.0{\%}). Each of the remaining GIP targets had a detection rate of ≤1.6{\%}. The recovery of bacteria for public health investigations varied, with rates as high as 77{\%} for Salmonella to as low as 30{\%} for Yersinia enterocolitica. Of stools positive for C. difficile on the GIP that were tested by EIA, only 42.7{\%} (88/206) were found to be producing detectable toxin. Overall, the implementation of the GIP resulted in high detection rates of GI pathogens, including the frequent detection of coinfections. This is a promising test to streamline the testing of agents causing infectious gastroenteritis from multiple tests down to a single order with limited hands-on time. Ongoing studies will need to assess the impact that the GIP has on downstream patient care and public health practices.",
author = "Murphy, {C. N.} and Fowler, {R. C.} and Iwen, {Peter Charles} and Fey, {Paul D}",
year = "2016",
month = "12",
day = "12",
doi = "10.1007/s10096-016-2858-7",
language = "English (US)",
pages = "1--8",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Evaluation of the BioFire FilmArray® GastrointestinalPanel in a Midwestern Academic Hospital

AU - Murphy, C. N.

AU - Fowler, R. C.

AU - Iwen, Peter Charles

AU - Fey, Paul D

PY - 2016/12/12

Y1 - 2016/12/12

N2 - The BioFire FilmArray® Gastrointestinal Panel (GIP) was implemented to replace traditional stool culture and enzyme immunoassay (EIA) testing for stool pathogens. The purpose of this study was to evaluate the detection rate, incidence of coinfection, and culture recovery rate of gastrointestinal (GI) pathogens detected by the GIP over a 1-year period. A total of 2257 stools collected from January to December 2015 were tested using the GIP. Clostridium difficile colonization was also evaluated by an antigen/toxin EIA and confirmatory polymerase chain reaction (PCR). The GIP detected one pathogen in 911 (40.4%) specimens. Coinfections were detected in 176 (7.8%) of these specimens. The most frequently detected pathogens were C. difficile (15.2%), norovirus (8.9%), enteropathogenic Escherichia coli (7.1%), enteroaggregative E. coli (3.4%), Campylobacter spp. (2.3%), and sapovirus (2.0%). Each of the remaining GIP targets had a detection rate of ≤1.6%. The recovery of bacteria for public health investigations varied, with rates as high as 77% for Salmonella to as low as 30% for Yersinia enterocolitica. Of stools positive for C. difficile on the GIP that were tested by EIA, only 42.7% (88/206) were found to be producing detectable toxin. Overall, the implementation of the GIP resulted in high detection rates of GI pathogens, including the frequent detection of coinfections. This is a promising test to streamline the testing of agents causing infectious gastroenteritis from multiple tests down to a single order with limited hands-on time. Ongoing studies will need to assess the impact that the GIP has on downstream patient care and public health practices.

AB - The BioFire FilmArray® Gastrointestinal Panel (GIP) was implemented to replace traditional stool culture and enzyme immunoassay (EIA) testing for stool pathogens. The purpose of this study was to evaluate the detection rate, incidence of coinfection, and culture recovery rate of gastrointestinal (GI) pathogens detected by the GIP over a 1-year period. A total of 2257 stools collected from January to December 2015 were tested using the GIP. Clostridium difficile colonization was also evaluated by an antigen/toxin EIA and confirmatory polymerase chain reaction (PCR). The GIP detected one pathogen in 911 (40.4%) specimens. Coinfections were detected in 176 (7.8%) of these specimens. The most frequently detected pathogens were C. difficile (15.2%), norovirus (8.9%), enteropathogenic Escherichia coli (7.1%), enteroaggregative E. coli (3.4%), Campylobacter spp. (2.3%), and sapovirus (2.0%). Each of the remaining GIP targets had a detection rate of ≤1.6%. The recovery of bacteria for public health investigations varied, with rates as high as 77% for Salmonella to as low as 30% for Yersinia enterocolitica. Of stools positive for C. difficile on the GIP that were tested by EIA, only 42.7% (88/206) were found to be producing detectable toxin. Overall, the implementation of the GIP resulted in high detection rates of GI pathogens, including the frequent detection of coinfections. This is a promising test to streamline the testing of agents causing infectious gastroenteritis from multiple tests down to a single order with limited hands-on time. Ongoing studies will need to assess the impact that the GIP has on downstream patient care and public health practices.

UR - http://www.scopus.com/inward/record.url?scp=85004073486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004073486&partnerID=8YFLogxK

U2 - 10.1007/s10096-016-2858-7

DO - 10.1007/s10096-016-2858-7

M3 - Article

SP - 1

EP - 8

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

ER -